It was announced today that the 2019 Wolf Prize for Chemistry has been awarded to professors John F. Hartwig from University of California at Berkeley and Stephen L. Buchwald from MIT, for the development of efficient transition-metal catalysts that have revolutionized drug manufacturing, leading to breakthrough in molecule and synthetics design.
In the modern age of pharmacology, some of the newest heroes in the war against human disease are biologists and chemists working in chemical proteomics. Among the leaders in this research is the Novartis-Berkeley Center for Proteomics and Chemistry Technologies (NB-CPACT), a joint venture linking Novartis, a large pharmaceutical company, and the world’s leading public research university. Launched in October 2017, the center is developing new technologies to further the discovery of next-generation therapeutics for cancer and other diseases.
The College is pleased to announce C. Judson King's A History of Berkeley Chemical Engineering: Pairing Engineering and Science is now available on eScholarship, Berkeley's flagship scholarly repository, and as a print book from...
Willard Libby (B.S. '31, Chem; Ph.D. '33, Chem) of Chicago University realized that the radioactivity generated by carbon-14 could be exploited to tremendous advantage.
It was announced today that the 2019 Wolf Prize for Chemistry has been awarded to professors John F. Hartwig from University of California at Berkeley and Stephen L. Buchwald from MIT, for the development of efficient transition-metal catalysts that have revolutionized drug manufacturing, leading to breakthrough in molecule and synthetics design.
